Uncategorized
calendar_month Nov 19, 2026

Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial

Clinical-stage biotechnology company Immutep Limited (NASDAQ:IMMP) announced Phase 2 data showing an 81.1% 12-month disease-free survival rate for its combination regimen in high-risk, resectable soft tissue sarcoma.

The Australia-based developer of LAG-3 immunotherapies for cancer and autoimmune diseases presented EFTISARC-NEO study findings at the Connective Tissue Oncology Society.

The investigator-initiated trial evaluates eftilagimod alfa, or efti, with Merck & Co. Inc. (NYSE:MRK) Keytruda (pembrolizumab) and radiotherapy before surgery.

Strong Survival Rates In Soft Tissue Sarcoma

Researchers enrolled 40 patients, and surgeons operated on 38 participants who entered the survival evaluation.

At the April 30, 2026, data cutoff, eight of those 38 patients had experienced disease recurrence over a 19.1-month median follow-up.

Mature results confirmed an 81.1% 12-month disease-free survival rate.

Current Kaplan-Meier estimates also show an 81.1% disease-free survival rate at 18 months, though this figure remains immature with ongoing follow-up.

Patients also achieved a 94.1% 12-month local recurrence-free survival rate and an 86.2% 12-month distant metastasis-free survival rate.

Immune Biomarkers Link To Better Survival

Exploratory analyses associated higher post-treatment tumor-infiltrating lymphocytes and greater tissue hyalinization and fibrosis with improved disease-free survival.

Patients with tumor-infiltrating lymphocytes above 310 cells/mm² achieved a 95.0% 12-month disease-free survival rate, compared with 64.9% for lower levels.

Patients with treatment-related hyalinization and fibrosis exceeding 52% reached a 93.8% 12-month disease-free survival rate, versus 71.4% for lower levels.

Tertiary lymphoid structures and baseline expression of PD-L1, LAG-3, and TIGIT did not correlate with survival outcomes.

Mechanism And Next Clinical Steps

These findings build on earlier EFTISARC-NEO data meeting the primary endpoint with a 51.5% median tumor hyalinization and fibrosis rate.

The data match efti’s mechanism of activating antigen-presenting cells to drive stronger anti-tumor T-cell responses.

Immutep anticipates reporting more EFTISARC-NEO data in calendar year 2027.

The company plans to start a registration-directed clinical trial in neoadjuvant soft tissue sarcoma in the second half of calendar year 2027.

IMMP Price Action: Immutep shares were up 7.69% at $3.50 during premarket trading on Thursday. The stock is trading near its 52-week low of $2.66, according to Benzinga Pro data.

Photo via Shutterstock